Investment Rating - The report maintains a "Buy" rating for the company [12] Core Insights - The company achieved a revenue of 31.603 billion (+14.43%) and a net profit attributable to shareholders of 3.421 billion (+1.58%) in 2025, with a significant increase in cash flow from operating activities by 25.23% to 5.513 billion [1][4] - The business structure has changed significantly due to acquisitions, with the self-medication (CHC) business experiencing a revenue decline of 14.67% to 15.111 billion, while the prescription drug business benefited from the consolidation of Tian Shi Li, achieving a revenue of 12.094 billion (+101.38%) [1][2] Financial Performance - The company’s revenue is projected to grow to 34.691 billion in 2026, 37.967 billion in 2027, and 41.103 billion in 2028, with net profit expected to reach 3.813 billion, 4.296 billion, and 4.669 billion respectively [4][14] - The earnings per share (EPS) is forecasted to be 2.29, 2.58, and 2.81 yuan for 2026, 2027, and 2028 respectively [4][14] Business Strategy - The company has established a "One Body, Two Wings" strategy, focusing on CHC as the core and leveraging the strengths of Tian Shi Li in prescription drugs, while also integrating with Kun Yao Group to enhance its market position in consumer health, medical health, and senior health sectors [2][3] - The company’s R&D investment reached 1.734 billion in 2025, with significant achievements in traditional Chinese medicine and innovative collaborations in various therapeutic areas [3][4]

Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 33.64 CNY, compared to the current stock price of 27.99 CNY as of March 26, 2026 [3]. Core Insights - The company achieved a revenue of 31.603 billion CNY in 2025, representing a year-on-year growth of 14.43%. The net profit attributable to shareholders was 3.421 billion CNY, with a growth of 1.58% year-on-year. The fourth quarter showed a strong recovery with a revenue of 9.616 billion CNY, up 22.09% year-on-year, and a net profit of 1.068 billion CNY, up 161.77% year-on-year [1][2]. - The gross margin for 2025 was 54.03%, an increase of 2.17 percentage points year-on-year. The company maintained good control over overall expense ratios, with a total expense ratio of 38.89%, up 3.93 percentage points year-on-year [1]. - The company has established a robust business structure with the integration of Tian Shi Li, leading to significant growth in the prescription drug segment, which saw a revenue increase of 101.38% year-on-year [2][3]. Financial Performance - In 2025, the CHC business generated a revenue of 15.111 billion CNY, a decline of 14.67% year-on-year, while the prescription drug business generated 12.094 billion CNY, reflecting a substantial increase due to the merger with Tian Shi Li [2]. - The company successfully completed its strategic goal of doubling revenue during the "14th Five-Year Plan" period, increasing the number of products exceeding 100 million CNY from 21 to 45 [3][6]. - Forecasts for revenue growth from 2026 to 2028 are 8.4%, 7.6%, and 7.4%, respectively, with net profit growth of 9.1%, 8.8%, and 8.7% [6][7]. Business Strategy - The company aims to benchmark against world-class enterprises during the "15th Five-Year Plan" period, focusing on product excellence, brand recognition, and innovation in traditional Chinese medicine [6]. - The company has enhanced its R&D investment from 581 million CNY in 2020 to 1.734 billion CNY in 2025, with a total of 38 approved products [6].

Investment Rating - The report maintains a "Buy" rating for China Resources Sanjiu (000999.SZ) [3][7]. Core Views - The company's "one body, two wings" strategy has shown effectiveness, driving growth through innovation and acquisitions [7]. - The revenue for 2025 is projected at 31.603 billion yuan, with a year-on-year growth of 14.43%, while the net profit attributable to shareholders is expected to be 3.421 billion yuan, reflecting a year-on-year increase of 1.58% [7]. - The report anticipates revenue growth for 2026 to 2028 at 10.6%, 9.4%, and 8.8% respectively, with net profit growth rates of 10.8%, 13.3%, and 11.5% [7]. Financial Forecasts and Indicators - **Revenue Forecast**: - 2025: 31,603 million yuan - 2026: 34,937 million yuan - 2027: 38,208 million yuan - 2028: 41,582 million yuan - Growth Rates: 14.4% (2025), 10.6% (2026), 9.4% (2027), 8.8% (2028) [3][8] - **Net Profit Forecast**: - 2025: 3,421 million yuan - 2026: 3,792 million yuan - 2027: 4,296 million yuan - 2028: 4,791 million yuan - Growth Rates: 1.6% (2025), 10.8% (2026), 13.3% (2027), 11.5% (2028) [3][8] - **Earnings Per Share (EPS)**: - 2025: 2.06 yuan - 2026: 2.28 yuan - 2027: 2.58 yuan - 2028: 2.88 yuan [3][8] - **Valuation Ratios**: - Price-to-Earnings (P/E): 14 (2025), 12 (2026), 11 (2027), 10 (2028) - Price-to-Book (P/B): 2.1 (2025), 2.0 (2026), 1.8 (2027), 1.6 (2028) [3][8] Business Segments - **Consumer Health Care (CHC)**: - Revenue: 151.11 billion yuan, accounting for 47.81% of total revenue, with a gross margin of 61.67% [7]. - **Prescription Drugs**: - Revenue: 120.94 billion yuan, accounting for 38.27% of total revenue, with a gross margin of 58.81% [7]. Dividend Policy - The company distributed a total cash dividend of 1.731 billion yuan in 2025, with a payout ratio of 50.59% and a dividend yield of 3.65% [7].

股票代码：000999 股票简称：华润三九 公告编号：2026—014 华润三九医药股份有限公司 关于控股股东的股东华润医药集团有限公司 董事会 二○二六年三月二十五日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 华润三九医药股份有限公司（以下简称"公司"）接控股股东华润医药控股 有限公司（以下简称"华润医药控股"）通知，华润医药控股的控股股东华润医 药集团有限公司（以下简称"华润医药集团"）于 2026 年 3 月 25 日在香港联合 交易所有限公司（以下简称"香港联交所"）刊发了 2025 年业绩公告。 公司投资者如需了解华润医药集团 2025 年业绩公告的详细信息，请查询香 港联交所网站：http://www.hkexnews.hk。 特此公告。 华润三九医药股份有限公司 刊发 2025 年业绩公告的提示性公告 ...

Financial Performance - In 2025, the company achieved a revenue of CNY 31.603 billion, representing a year-on-year growth of 14.43% [3] - The net profit attributable to shareholders was CNY 3.421 billion, with a growth of 1.58% [3] - The net cash flow from operating activities reached CNY 5.513 billion, increasing by 25.23% compared to the previous year [3] - The overall gross margin for 2025 was 54.03%, up by 2.17 percentage points year-on-year [4] Business Segments - The CHC (Consumer Health Care) segment generated revenue of CNY 15.111 billion, a decline of 14.67% [3] - The prescription drug segment saw revenue of CNY 12.094 billion, a significant increase of 101.38% [3] R&D and Innovation - R&D investment for 2025 was CNY 1.734 billion, focusing on cardiovascular, oncology, digestive metabolism, and respiratory treatments [5] - The company achieved multiple project collaborations and received several drug registration certificates, enhancing its product portfolio [5][6] Market Strategy - The company aims to maintain its leadership in the respiratory and skin care markets while expanding its product offerings [7] - The prescription drug business is guided by clinical value, with a focus on innovation and collaboration [8] Shareholder Returns - The proposed dividend for 2025 is CNY 5.90 per 10 shares, totaling approximately CNY 1.73 billion, which is 50.59% of the net profit [8] - Cumulative dividends since the company's listing have exceeded CNY 10 billion [25] Future Outlook - The company anticipates that the pharmaceutical industry will continue to face challenges in 2026, but expects to exceed the average industry growth rate [9] - The strategic focus for the "15th Five-Year Plan" includes enhancing R&D capabilities and leveraging AI for digital transformation [11][29] Market Trends - The company recognizes the ongoing shift towards digitalization in retail, with online sales expected to exceed 10% of total sales by 2025 [17] - The aging population trend is driving the need for health products, aligning with the company's strategic focus on health care [29]

股票代码：000999 股票简称：华润三九 公告编号：2026—011 华润三九医药股份有限公司 关于公司控股子公司昆药集团 2026 年度担保计划的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、控股子公司担保情况概述 2026 年度，为适应公司控股子公司昆药集团股份有限公司（以下简称"昆 药集团"）及其相关下属公司业务发展需要，满足相关公司融资担保需求，昆药 集团及其下属子/孙公司预计为不超过人民币 1.169 亿元的银行融资授信业务提 供连带责任担保，占昆药集团最近一期经审计净资产的 2.18%，占华润三九最近 一期经审计净资产的 0.53%。其中，为资产负债率超过 70%的子/孙公司不超过 0.762 亿元的银行融资授信业务提供连带责任担保，占昆药集团最近一期经审计 净资产的 1.42%，占华润三九最近一期经审计净资产的 0.34%；为资产负债率不 超过 70%的子/孙公司不超过 0.407 亿元的银行融资授信业务提供连带责任担保， 占昆药集团最近一期经审计净资产的 0.76%，占华润三九最近一期经审计净资产 的 0.18%。其中，昆药集团本 ...

2026 年 3 月 23 日，公司董事会 2026 年第四次会议以 11 票同意、0 票反对、 0 票弃权的表决结果审议通过了《关于公司控股子公司天士力 2026 年度担保计 划的议案》。该议案尚需提交公司下一次股东会审议。 股票代码：000999 股票简称：华润三九 公告编号：2026—012 华润三九医药股份有限公司 关于公司控股子公司天士力 2026 年度担保计划的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、控股子公司担保情况概述 2026 年度，为适应公司控股子公司天士力医药集团股份有限公司（以下简 称"天士力"）相关下属公司业务发展需要，满足相关公司融资担保需求，天士 力预计为天津天士力医药商业有限公司（以下简称"天士力商业"）、江苏鸿泰药 业有限公司（以下简称"江苏鸿泰"）不超过人民币 8 亿元的银行融资授信业务 提供连带责任担保，占天士力最近一期经审计净资产的 6.45%，占华润三九最近 一期经审计净资产的 3.61%。天士力商业、江苏鸿泰资产负债率均不超过 70%。 二、担保预计情况 为适应天士力商业、江苏鸿泰 2026 年生产 ...

1．股东会届次：2025 年年度股东会 2．股东会的召集人：董事会 股票代码：000999 股票简称：华润三九 公告编号：2026—013 华润三九医药股份有限公司 关于召开 2025 年年度股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要提示： 1、本次股东会无否决议案。 2、本次股东会不涉及变更前次股东会已通过的决议。 一、召开会议基本情况 3．本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所 股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公 司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》的有关 规定。本次股东会由公司第九届董事会 2026 年第四次会议决定召开。 4．会议时间： （1）现场会议时间：2026 年 04 月 16 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026 年 04 月 16 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易 所互联网投票系统投票的具体时间为 2026 年 04 ...

股票代码：000999 股票简称：华润三九 公告编号：2026—010 详细内容请参见《华润三九医药股份有限公司关于公司控股子公司天士力 2026 年度担保计划的公告》（2026-012）。 表决结果：同意 11 票，反对 0 票，弃权 0 票，审议通过。 华润三九医药股份有限公司 2026 年第四次董事会会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 华润三九医药股份有限公司董事会 2026 年第四次会议于 2026 年 3 月 23 日 在华润三九医药股份有限公司综合办公中心 108 会议室以现场会议方式召开。会 议通知以书面方式于 2026 年 3 月 20 日发出。会议由董事长邱华伟先生主持，本 次会议应到董事 11 人，实到董事 11 人，公司部分高级管理人员列席会议。本次 会议的召开及程序符合《公司法》和《公司章程》的规定，会议合法有效。会议 以投票方式审议通过了以下议案，并形成决议： 一、关于公司控股子公司昆药集团 2026 年度担保计划的议案 详细内容请参见《华润三九医药股份有限公司关于公司控股子公司昆药集团 2026 年度担保计 ...

Investment Rating - The report suggests a positive investment outlook for the innovative drug sector, highlighting potential opportunities due to upcoming clinical data and successful overseas clinical progress of pipelines [2][4]. Core Insights - The chemical products sector is experiencing significant price increases due to rising international oil prices and high overseas energy costs, particularly affecting solvent products which are difficult to stockpile [1][10]. - The raw material pharmaceutical products are expected to see price increases as upstream raw material costs rise, with downstream clients maintaining low inventory levels since April 2023, indicating a potential for sustained price increases and profit elasticity [1][10]. - The report emphasizes the importance of the PI3K/AKT/mTOR signaling pathway in cancer treatment, with renewed focus on PI3K inhibitors, particularly following Novartis's acquisition of Synnovation Therapeutics' PI3Kα inhibitor SNV4818 [34][35][36]. Summary by Sections Raw Materials - The report notes that the pharmaceutical raw material sector is poised for price increases due to rising upstream costs and low inventory levels among clients, which could lead to sustained profitability [1][10]. Pharmaceuticals - Novartis announced a $2 billion upfront payment and up to $1 billion in milestone payments to acquire Synnovation Therapeutics' PI3Kα inhibitor SNV4818, indicating a strategic focus on differentiated therapies in the HR+/HER2- breast cancer market [2][34]. Medical Devices - Innovative products in the medical device sector are expanding into international markets, with companies like MicroPort receiving CE certification for pediatric applications of their surgical robots, enhancing their global brand presence [3][11]. Biologics - The report highlights the promising results of the oral GLP-1 Aleniglipron, which showed significant weight loss in clinical trials, suggesting a shift towards oral formulations that improve patient compliance and reduce logistics costs [3][12]. Traditional Chinese Medicine - The report suggests monitoring undervalued high-dividend assets within the traditional Chinese medicine sector as companies begin to release their performance results [3][12]. Healthcare Services and Consumer Healthcare - The report discusses the upcoming release of the DRG/DIP 3.0 version by the National Healthcare Security Administration, expected to be published around July 2023, which will provide insights into the evolving healthcare payment landscape [3][12]. Investment Recommendations - The report recommends focusing on core sectors such as small nucleic acids, bispecific antibodies, and ADCs, while also identifying opportunities during earnings forecast windows and major clinical data release events [2][4].